MNKD Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $3.80
Kapitalisasi Pasar (MRQ) $1.18B
P/E (TTM) -29.2
EPS (TTM) $-0.13
Pendapatan (TTM) $394M
ROE (TTM) 71.4%
Rentang 52M $2–$7

MNKD Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Pemecahan saham 1
Tanggal ex-dividen Pemecahan Tipe
3 Maret 2017 1-for-5 Terbalik

Tentang MannKind Corporation - Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.

MannKind Corporation was named after its founder, Alfred E. Mann.

History

Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

The FDA approved Afrezza on June 27, 2014.

On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.

In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.

Products and product candidates

The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.

Leadership

Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.

In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.

Facilities

MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan591 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$349M
2016-12-31 → 2025-12-31
EPS$0.02
2016-12-31 → 2025-12-31
Arus Kas Bebas$14M
2018-12-31 → 2025-12-31
Margin bersih-11.1%
2017-12-31 → 2025-12-31
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun MNKD rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) -29.2rata-rata 5T ≈45.5 ≈45.5 · ·
P/S (TTM) 3.0rata-rata 5T ≈9.1 ≈9.1 21.2 Kurang nilai
P/B (MRQ) -17.5rata-rata 5T ≈-14.7 ≈-14.7 · ·
Harga / FCF (TTM) -64.9rata-rata 5T ≈7.7 ≈7.7 · ·
Harga / Arus Kas (TTM) -146.2rata-rata 5T ≈27.0 ≈27.0 · ·
Harga / Nilai Buku Berwujud (MRQ) -16.3 · · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata -86.3%
Laporan Berikutnya Nov 03, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Agu 12, 2026 $-0.06 $-0.00 —
31 Maret 2026 Mei 13, 2026 $-0.05 $-0.00 —
31 Des. 2025 $-0.05 $0.01 -440.1%
30 Sep. 2025 $0.07 $0.02 205.9%
30 Juni 2025 $0.00 $0.05 -100.0%
31 Maret 2025 $0.04 $0.04 -10.9%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 16
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $349M$286M$199M$100M$75M$65M$63M$28M$12M$175M$0$0
Cost of Revenue $27M$17M$21M$16M$17M$15M$20M$19M$17M$17M$65M·
SG&A Expense $144M$94M$94M$91M$32M$25M$75M$80M$75M$47M$41M$79M
Operating Expenses $88M$77M$63M$57M$39M$25M$108M$104M$120M$107M$345M$180M
Operating Income $39M$73M$9M$-64M$-47M$-48M$-45M$-77M$-108M$67M$-345M$-180M
Interest Expense ··$15M$15M$15M·····$24M$20M
Interest Income $8M$13M$6M$3M$112.0K$167.0K$997.0K$501.0K$293.0K$85.0K$18.0K$9.0K
Other Non-op $-1M$32.0K$122.0K$-102.0K$-239.0K$23.0K$-926.0K$-437.0K$13.0K$-597.0K$1M$2M
Pretax Income $1M$31M$-10M$-87M$-81M$-57M$-52M$-87M$-117M$126M$-368M$-198M
Income Tax $-4M$3M$2M$0$0$-218.0K$0$240.0K$51.0K$0$0$0
Net Income $6M$28M$-12M$-87M$-81M$-57M$-52M$-87M$-117M$126M$-368M$-198M
EPS (Basic) $0.02$0.10$-0.04$-0.34$-0.32$-0.26·$-0.60$-1.13$1.37$-4.54$-2.57
EPS (Diluted) $0.02$0.10$-0.04$-0.34$-0.32$-0.26·$-0.60$-1.13$1.36$-4.54$-2.57
Shares (Basic) 305,639,000274,415,000267,014,000257,092,000249,244,000222,585,000·144,136,000104,245,00092,053,00081,233,00077,045,000
Shares (Diluted) 314,112,000283,844,000267,014,000257,092,000249,244,000222,585,000·144,136,000104,245,00092,085,00081,233,00077,045,000
EBITDA $39M$73M$9M$-64M$-47M$-48M$-45M$-77M$-106M·$-334M$-170M
Neraca 28
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $75M$46M$238M$70M$124M$67M$30M$71M$44M$23M$59M$121M
Short-term Investments $96M$151M$57M$101M$80M$0$20M·····
Receivables $38M$12M$15M$17M$5M$4M$4M$4M$3M$302.0K$23.0K$50M
Inventory $35M$28M$29M$22M$7M$5M$4M$4M$3M$2M·$10M
Prepaid Expense $47M$31M$35M$25M$3M$3M$3M$3M$3M$4M$4M$20M
Current Assets $292M$268M$373M$235M$219M$79M$61M$82M$57M$77M$77M$201M
PP&E (Net) $82M$85M$84M$45M$37M$26M$27M$26M$27M$29M$49M$192M
PP&E (Gross) $196M$192M$186M$144M$134M$123M$122M$126M$128M$129M$168M$310M
Accum. Depreciation $114M$107M$102M$99M$98M$97M$95M$100M$101M$100M$120M$118M
Goodwill $68M$2M$2M$2M········
Intangibles $5M$5M$1M$1M········
Other Non-current Assets $20M$27M$7M$10M$8M$3M$6M$249.0K$437.0K$648.0K$1M$848.0K
Total Assets $792M$394M$475M$295M$321M$109M$94M$108M$85M$107M$126M$394M
Accounts Payable $9M$7M$10M$11M$7M$6M$5M$5M$7M$3M$16M$7M
Accrued Liabilities $65M$40M$42M$36M$27M$20M$16M$15M$12M$8M$8M$26M
Short-term Debt ······$5M·····
Current Liabilities $171M$82M$104M$67M$48M$74M$66M$75M$88M$92M$268M$403M
Capital Leases $11M$12M$4M$5M$1M$1M$3M·····
Other Non-current Liabilities ····$5M·····$15M$12M
Total Liabilities $843M$473M$721M$546M$531M$289M$284M$283M$299M$291M$477M$468M
Long-term Debt $355M$36M$269M$273M$281M$122M$119M$102M$157M···
Total Debt ······$5M·····
Common Stock $3M$3M$3M$3M$3M$2M$2M$2M$1M$957.0K$4M$4M
Retained Earnings $-3.20B$-3.20B$-3.23B$-3.22B$-3.13B$-3.05B$-2.99B$-2.94B$-2.85B$-2.74B$-2.86B$-2.49B
AOCI $115.0K$1M····$-19.0K$-19.0K$-18.0K$-24.0K$-20.0K$-14.0K
Stockholders' Equity $-51M$-79M$-246M$-251M$-209M$-180M$-191M$-175M$-215M$-184M$-350M$-74M
Liabilities + Equity $792M$394M$475M$295M$321M$109M$94M$108M$85M$107M$126M$394M
Shares Outstanding 307,832,587302,959,782270,034,495263,793,305251,477,562242,117,089211,787,573187,029,967119,053,41495,680,83185,734,188406,059,089
Arus Kas 18
Metrik Tren 202520242023202220212020201920182017201620152014
D&A $12M$7M$5M$3M$2M$2M$972.0K$3M$2M$2M$11M$10M
Stock-based Comp $24M$21M$18M$13M$12M$7M$6M$7M$5M$5M$9M$49M
Deferred Tax $-19M$4M$7M$-10M$-20M$-5M$-5M$-11M$-260M$48M$-80M$-66M
Amort. of Intangibles $4M···········
Restructuring ·········$2M$6M$2M
Other Non-cash ········$306M·$291M$144M
Operating Cash Flow $18M$43M$34M$-81M$-62M$-28M$-88M$-38M$-65M$-78M$-57M$4M
CapEx $5M$10M$42M$8M$11M$801.0K$3M$354.0K·$1M$10M$24M
Investing Cash Flow $-305M$-97M$-2M$5M$-152M$15M$-23M$-234.0K$17M$-1M··
Debt Issued ·····$5M·····$20M
Net Debt Issued ·····$5M······
Stock Issued ········$564.0K$893.0K$28M·
Net Stock Activity ········$564.0K·$28M·
Financing Cash Flow $315M$-137M$137M$21M$270M$50M$70M$61M$74M$43M··
Net Change in Cash $29M$-191M$169M$-54M$57M$37M$-41M$23M$25M$-36M$-62M$50M
Taxes Paid $2M$4M··········
Free Cash Flow $14M$33M$-8M$-88M$-73M$-29M$-91M$-38M··$-68M$-20M
Levered FCF ··$-26M$-98M······$-92M·
Profitabilitas 7
Metrik Tren 202520242023202220212020201920182017201620152014
Operating Margin 11.1%25.4%4.4%-64.3%-62.3%-73.6%-70.8%-274.9%-921.1%···
Net Margin 1.7%9.7%-6.0%-87.6%-107.3%-87.9%-82.3%-312.2%-999.0%···
Pretax Margin 0.40%10.7%-5.2%-87.6%-107.3%-88.2%-82.3%-311.3%-998.6%···
EBITDA Margin 11.1%25.4%4.4%-64.3%-62.3%-73.6%-70.8%-274.9%-905.8%···
ROA 0.99%6.3%-3.1%-28.4%-37.7%-56.6%-51.5%-90.5%-122.4%·-141.5%-60.8%
ROE -11.1%-19.1%4.8%35.8%41.1%31.2%27.7%45.7%58.9%·173.8%379.7%
ROIC -316.9%-83.2%-4.1%25.6%22.5%26.5%24.0%43.9%50.4%·98.4%·
Likuiditas & Solvabilitas 4
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 1.73.33.63.54.51.10.91.10.7·0.30.5
Quick Ratio 1.22.63.02.84.31.00.81.00.5·0.20.4
Debt / Equity ······-0.0·····
Interest Coverage ··0.6-6.7······-14.3-8.8
Efisiensi 3
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.60.70.50.30.40.60.60.30.1·0.0·
Inventory Turnover 0.80.60.81.12.83.35.26.26.9···
Receivables Turnover 13.921.412.69.316.416.916.78.27.6·0.0·
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $-0.17$-0.26$-0.91$-0.95$-0.83$-0.75$-0.90$-0.94$-1.80·$-0.82$-0.18
Revenue / Share $1.11$1.01$0.75$0.39···$0.19$0.11···
Cash Flow / Share $0.06$0.15$0.13$-0.31···$-0.26$-0.62···
Cash / Share $0.24$0.15$0.88$0.26$0.49$0.28$0.14$0.38$0.37·$0.14$0.30
EPS (TTM) $0.02$0.10$-0.04$-0.34$-0.32$-0.26$-0.63$-0.60$-1.13$1.36$-4.54$-2.57
Tingkat Pertumbuhan 5
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 22.2%43.5%99.4%32.2%15.8%·······
Revenue CAGR 3Y 51.8%55.8%45.1%·········
Revenue CAGR 5Y 39.9%···········
EPS YoY -80.0%···········
Net Income YoY -78.8%···········
Valuasi (TTM) 13
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $349M$286M$199M$100M$75M$65M$63M$28M$12M$175M$0$0
Net Income TTM $6M$28M$-12M$-87M$-81M$-57M$-52M$-87M$-117M$126M$-368M$-198M
Market Cap $1.75B$1.95B$983M$1.39B$1.10B$758M$273M$198M$276M·$3.11B$10.60B
Enterprise Value ······$228M·····
P/E 283.564.3-91.0-15.5-13.7-12.0-2.0-1.8-2.12.4-1.6-10.2
P/S 5.06.84.913.914.611.64.37.123.5···
P/B -34.2-24.7-4.0-5.5-5.2-4.2-1.4-1.1-1.3·-8.9-143.7
P / Cash Flow 95.645.828.8-17.2-17.8-26.9-3.1-5.3-4.3·-54.32593.8
P / FCF 127.559.4-117.8-15.7-15.0-26.2-3.0-5.2··-46.0-529.6
EV / EBITDA ······-5.1·····
EV / FCF ······-2.5·····
EV / Revenue ······3.6·····
Earnings Yield 0.35%1.6%-1.1%-6.5%-7.3%-8.3%-48.8%-56.6%-48.7%42.5%-62.6%-9.8%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $349M $286M $199M $100M $75M
Margin Operasi % 11.1% 25.4% 4.4% -64.3% -62.3%
Laba Bersih $6M $28M $-12M $-87M $-81M
EPS Dilusian $0.02 $0.10 $-0.04 $-0.34 $-0.32

Pemilik institusional (13F) 271 pengaju · $883.4M total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 271
Nilai yang dipegang $883.4M
Posisi baru 51
Posisi yang keluar 39
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
51 (0 vs Kuartal sebelumnya) 39 (-8 vs Kuartal sebelumnya) 98 (+12 vs Kuartal sebelumnya) 63 (-7 vs Kuartal sebelumnya) +1.9M

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
BlackRock, Inc. $136.887.530 32.133.223 15,50% Saham
VANGUARD GROUP INC $101.384.549 17.880.873 11,48% Saham
Rubric Capital Management LP $76.680.000 18.000.000 8,68% Saham
STATE STREET CORP $68.901.423 16.174.043 7,80% Saham
VANGUARD CAPITAL MANAGEMENT LLC $56.101.610 13.169.392 6,35% Saham
GEODE CAPITAL MANAGEMENT, LLC $33.861.886 7.947.203 3,83% Saham
WELLINGTON MANAGEMENT GROUP LLP $33.418.878 7.844.807 3,78% Saham
Frazier Life Sciences Management, L.P. $28.116.000 6.600.000 3,18% Saham
Deep Track Capital, LP $25.560.000 6.000.000 2,89% Saham
180 WEALTH ADVISORS, LLC $21.126.835 4.959.351 2,39% Saham
FMR LLC $17.470.455 4.101.046 1,98% Saham
TSP Capital Management Group, LLC $16.923.596 3.972.675 1,92% Saham
AQR CAPITAL MANAGEMENT LLC $16.225.589 3.808.824 1,84% Saham
MORGAN STANLEY $14.802.946 3.474.870 1,68% Saham
BRAIDWELL LP $14.732.908 3.458.429 1,67% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $12.789.240 3.002.169 1,45% Saham
NORTHERN TRUST CORP $12.299.856 2.887.290 1,39% Saham
UBS Group AG $12.295.344 2.886.231 1,39% Saham
TWO SIGMA INVESTMENTS, LP $11.475.213 2.693.712 1,30% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $11.070.577 2.598.727 1,25% Saham
BANK OF AMERICA CORP /DE/ $10.074.356 2.364.872 1,14% Saham
VANGUARD FIDUCIARY TRUST CO $9.358.279 2.196.779 1,06% Saham
GOLDMAN SACHS GROUP INC $9.178.165 2.154.499 1,04% Saham
WELLS FARGO & COMPANY/MN $6.289.519 1.476.413 0,71% Saham
SUSQUEHANNA INTERNATIONAL GROUP, LLP $5.030.221 1.180.803 0,57% Saham
DIMENSIONAL FUND ADVISORS LP $4.661.185 1.094.192 0,53% Saham
Caption Management, LLC $4.260.000 1.000.000 0,48% Opsi jual
Bank of New York Mellon Corp $3.827.454 898.463 0,43% Saham
CITADEL ADVISORS LLC $3.818.068 896.260 0,43% Saham
J. Goldman & Co LP $3.478.669 816.589 0,39% Saham
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $3.019.973 1.232.642 0,34% Saham
SCOPIA CAPITAL MANAGEMENT LP $2.960.534 694.961 0,34% Saham
Balyasny Asset Management L.P. $2.914.296 684.107 0,33% Saham
TWO SIGMA ADVISERS, LP $2.897.166 510.964 0,33% Saham
VICTORY CAPITAL MANAGEMENT INC $2.771.407 650.565 0,31% Saham
Nuveen, LLC $2.708.218 635.732 0,31% Saham
Swiss National Bank $2.502.324 587.400 0,28% Saham
STATE OF WISCONSIN INVESTMENT BOARD $2.177.052 511.045 0,25% Saham
JACOBS LEVY EQUITY MANAGEMENT, INC $2.106.540 494.493 0,24% Saham
1492 Capital Management LLC $2.052.136 481.722 0,23% Saham
Mariner, LLC $2.020.189 474.236 0,23% Saham
MILLENNIUM MANAGEMENT LLC $1.836.597 431.126 0,21% Saham
Schonfeld Strategic Advisors LLC $1.774.216 416.483 0,20% Saham
Squarepoint Ops LLC $1.759.644 413.062 0,20% Saham
Jefferies Financial Group Inc. $1.694.202 397.700 0,19% Saham
ExodusPoint Capital Management, LP $1.666.261 391.141 0,19% Saham
JANE STREET GROUP, LLC $1.658.418 389.300 0,19% Opsi beli
PRINCIPAL FINANCIAL GROUP INC $1.629.561 382.526 0,18% Saham
Man Group plc $1.624.023 381.226 0,18% Saham
RHUMBLINE ADVISERS $1.604.647 376.681 0,18% Saham

Tampilkan semua 271 pemilik institusional →

Aktivis & pemilik 5%+ 2 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 pengajuan 10 Juli 2012 · Pengajuan awal Investasi pasif SEC
Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan, Orang pelapor yang tidak diungkapkan 31 Jan. 2006 · Pengajuan awal · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 43 orang dalam · 27 pejabat · 19 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Michael Castagna Chief Executive Officer 15 Juli 2026 M 2.433.779 1 4 $-990.292
Hakan Edstrom President & CEO 27 Agu 2015 A 1.114.340 0 0 $0
Christopher B Prentiss Chief Financial Officer 15 Juli 2026 F 318.668 0 0 $0
Juergen Martens Corporate VP and COO 27 Agu 2015 A 106.539 0 0 $0
Dominic Marasco Pres, Endocrine Business Unit 15 Juli 2026 F 343.398 0 0 $0
Sanjay R Singh EVP Technical Operations 15 Juli 2026 M 478.966 0 1 $-94.448
Stuart A Tross Chief People & Workpl Officer 15 Juli 2026 M 1.058.142 0 1 $-297.548
David Thomson EVP Genl Counsel & Secretary 15 Juli 2026 M 797.554 0 3 $-930.755
Ajay Ahuja Chief Medical Officer 23 Maret 2026 A 318.200 0 0 $0
Lauren M Sabella EVP Operations 15 Juli 2025 F 349.841 0 0 $0
Burkhard Blank EVP Chief Medical Officer 15 Juli 2025 F 460.791 0 0 $0
Joseph Kocinsky Chief Technology Officer 27 Agu 2022 F 745.233 0 0 $0
Alejandro Galindo EVP Endocrine Business Unit 28 Feb. 2022 A 576.690 0 0 $0
Rosabel Realica Alinaya VP, IR & Treasury 27 Agu 2020 A 167.119 0 0 $0
David M Kendall Chief Medical Officer 31 Juli 2020 P 41.059 0 0 $0
Patrick Mccauley Chief Commercial Officer 25 Feb. 2020 A 83.972 0 0 $0
Courtney Barton Chief Compl & Privacy Officer 31 Juli 2019 P 29.584 0 0 $0
Elizabeth Garrett Ingram Chief Marketing Officer 14 Mei 2019 A 43.012 0 0 $0
Raymond W. Urbanski Corp VP, CMO 10 Agu 2017 S 2.924 0 0 $0
Linda A Adreveno Sr. VP, HR 18 Feb. 2016 A 92.200 0 0 $0
Alfred E Mann Executive Chairman 22 Agu 2015 F 1.005.990 0 0 $0
Diane Palumbo Vice President, Human Resource 23 Feb. 2015 F 50.624 0 0 $0
Peter C Richardson Chief Scientific Officer 3 Maret 2012 F 133.611 0 0 $0
Richard L Anderson Corporate VP 16 Nov. 2008 F 204.401 0 0 $0
John R. Riesenberger VP & Chief Commercial Officer 13 Agu 2008 A 14.650 0 0 $0
Dan Burns VP & President, MKBP 8 Des. 2006 A 14.800 0 0 $0
Wendell W Cheatham VP, Medical & Reg Affairs 19 Agu 2004 A 300 0 0 $0
Steven B. Binder Direktur 25 Sep. 2026 S 713.258 0 5 $-683.703
Sabrina Kay Direktur 20 Mei 2026 A 265.600 0 0 $0
Jennifer Grancio Direktur 20 Mei 2026 A 244.815 0 0 $0
James Samuel Shannon Direktur 20 Mei 2026 A 64.635 0 0 $0
Michael A Friedman Direktur 20 Mei 2026 A 47.500 0 0 $0
Anthony C Hooper Direktur 20 Mei 2026 A 236.153 0 0 $0
Christine Mundkur Direktur 20 Mei 2026 A 254.493 0 0 $0
Ronald J Consiglio Direktur 20 Mei 2026 A 132.342 0 0 $0
Kent Kresa Direktur 15 Mei 2024 A 274.541 0 0 $0
Henry L Nordhoff Direktur 14 Mei 2019 A 103.426 0 0 $0
David Maccallum Direktur 16 Mei 2018 A 114.790 0 0 $0
Matthew J Pfeffer Direktur 28 Agu 2017 F 81.961 0 0 $0
Abraham E Cohen Direktur 17 Agu 2012 S 56.424 0 0 $0
Heather Hay Murren Direktur 13 Agu 2008 A 10.100 0 0 $0
Kathleen Connell Direktur 25 Mei 2006 A · 0 0 $0
Llew Keltner Direktur 25 Mei 2006 A · 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 29 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
JSMD · Janus Detroit Street Trust 0,62% 1.678.187 NS 31 Juli 2026 N-PORT
QQQS · Invesco Exchange-Traded Fund Trust … 0,52% 29.891 SH 2 Okt. 2026 Harian
JSML · Janus Detroit Street Trust 0,49% 450.643 NS 31 Juli 2026 N-PORT
FYC · First Trust Exchange-Traded AlphaDE… 0,37% 1.212.660 NS 31 Juli 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,23% 289.432 NS 31 Juli 2026 N-PORT
FYX · First Trust Exchange-Traded AlphaDE… 0,12% 409.547 NS 31 Juli 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0,09% 22.737 SH 2 Okt. 2026 Harian
IBB · iShares Trust 0,08% 2.264.902 SH 11 Sep. 2026 Harian
VTWG · VANGUARD SCOTTSDALE FUNDS 0,08% 330.117 SH 19 Agu 2026 Harian
IWO · iShares Trust 0,08% 2.877.921 SH 11 Sep. 2026 Harian
FAD · First Trust Exchange-Traded AlphaDE… 0,07% 109.855 NS 31 Juli 2026 N-PORT
PWS · Pacer Funds Trust 0,06% 3.954 NS 31 Juli 2026 N-PORT
ESML · iShares Trust 0,05% 333.357 SH 11 Sep. 2026 Harian
VTWO · VANGUARD SCOTTSDALE FUNDS 0,04% 1.771.496 SH 19 Agu 2026 Harian
RSSL · Global X Funds 0,04% 147.059 NS 31 Juli 2026 N-PORT
ISCG · iShares Trust 0,04% 96.772 SH 11 Sep. 2026 Harian
IWM · iShares Trust 0,04% 7.845.946 SH 11 Sep. 2026 Harian
VHT · VANGUARD WORLD FUND 0,02% 874.372 SH 19 Agu 2026 Harian
FHLC · FIDELITY COVINGTON TRUST 0,02% 139.696 NS 31 Juli 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0,01% 3.543.398 SH 19 Agu 2026 Harian
WSML · iShares Trust 0,01% 16.637 SH 11 Sep. 2026 Harian
TILT · FlexShares Trust 0,00% 23.700 NS 31 Juli 2026 N-PORT
ITOT · iShares Trust 0,00% 465.405 SH 11 Sep. 2026 Harian
IWV · iShares Trust 0,00% 84.120 SH 10 Sep. 2026 Harian
DFAC · Dimensional ETF Trust 0,00% 58.407 NS 31 Juli 2026 N-PORT
DFAS · Dimensional ETF Trust 0,00% 11.291 NS 31 Juli 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0,00% 9.327.332 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,00% 26.184 SH 19 Agu 2026 Harian
ISCB · iShares Trust · 13.557 SH 11 Sep. 2026 Harian

MNKD Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 14 analis BELI
Target median $7.50 +97,4%
4 28,6% Beli Kuat
8 57,1% Beli
2 14,3% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

8 analis · 2026-09-28

Target rata-rata $7.97 +109,7%

← Di bawah semua target Harga saat ini $3.80
Rendah$4.75 Rata-rata$7.97 Tinggi$13.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
MNKD $1.75B 283.5 22.2% 1.7% -11.1% ·
ORIC $806M -5.6 · · -36.5% ·
DMRA · · 38.3% -17981.1% -167.0% ·
REPL $633M -2.3 · · -146.2% ·
TRAX · · · · · ·
BCAX $953M -6.7 · · -33.0% ·
VOR $506M -0.2 · · 83.4% ·
MGTX $645M -5.6 144.6% -140.3% 8062.2% ·
JANX $833M -7.5 -5.5% -1136.2% -11.7% ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23

Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan

25

Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Agu 5, 2026